Table 1.
Overview of Stage I Samples
| Class | Diagnosis | Study Center (No. of samples) |
Total No. of Samples | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | |||
| C1 | Mature B-ALL with t(8;14) | 2 | 2 | 2 | 5 | 1 | 1 | 13 | |||||
| C2 | Pro-B-ALL with t(11q23)/MLL | 6 | 12 | 10 | 1 | 33 | 5 | 1 | 2 | 70 | |||
| C3 | c-ALL/pre-B-ALL with t(9;22) | 27 | 10 | 15 | 7 | 8 | 39 | 4 | 12 | 122 | |||
| C4 | T-ALL | 42 | 1 | 19 | 17 | 4 | 38 | 44 | 9 | 174 | |||
| C5 | ALL with t(12;21) | 16 | 23 | 1 | 18 | 58 | |||||||
| C6 | ALL with t(1;19) | 5 | 11 | 2 | 9 | 3 | 1 | 5 | 36 | ||||
| C7 | ALL with hyperdiploid karyotype | 1 | 14 | 2 | 14 | 2 | 7 | 40 | |||||
| C8 | c-ALL/pre-B-ALL without t(9;22) | 50 | 29 | 28 | 2 | 59 | 42 | 3 | 24 | 237 | |||
| C9 | AML with t(8;21) | 7 | 1 | 2 | 13 | 5 | 1 | 11 | 40 | ||||
| C10 | AML with t(15;17) | 2 | 2 | 8 | 5 | 4 | 3 | 13 | 37 | ||||
| C11 | AML with inv(16)/t(16;16) | 6 | 4 | 3 | 4 | 6 | 3 | 2 | 28 | ||||
| C12 | AML with t(11q23)/MLL | 4 | 4 | 5 | 6 | 17 | 1 | 1 | 38 | ||||
| C13 | AML with normal karyotype + other abnormalities | 2 | 60 | 1 | 12 | 63 | 117 | 19 | 9 | 41 | 27 | 351 | |
| C14 | AML complex aberrant karyotype | 4 | 3 | 2 | 28 | 2 | 1 | 6 | 2 | 48 | |||
| C15 | CLL | 15 | 35 | 41 | 81 | 45 | 32 | 199 | 448 | ||||
| C16 | CML | 5 | 44 | 15 | 12 | 76 | |||||||
| C17 | MDS | 28 | 71 | 3 | 1 | 56 | 44 | 3 | 206 | ||||
| C18 | Non-leukemia and healthy bone marrow | 19 | 19 | 17 | 16 | 3 | 74 | ||||||
| Total | 2,096 | ||||||||||||
NOTE. Two thousand ninety-six high-quality analyses were performed by 11 different study centers from seven countries across three continents. Eighteen diagnostic gold standard categories are given by their class subtype labels of C1 to C18 and are listed for each participating laboratory (laboratories 1 to 11).
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; MLL, myeloid/lymphoid or mixed-lineage leukemia; pre, precursor; c-ALL, childhood acute lymphoblastic leukemia; T-ALL, T-cell acute lymphoblastic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome.